ZSDT for mantle cell lymphoma after BTK inhibitor failure
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment called ZSDT for people with mantle cell lymphoma whose cancer did not respond to a BTK inhibitor. It aims to see if ZSDT can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have mantle cell lymphoma (a type of blood cancer) that came back or did not respond to a BTK inhibitor treatment.
- You have at least one tumor that can be measured on a scan.
- Your blood counts are high enough and your liver and kidneys are working well enough.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with mantle cell lymphoma that has come back or stopped responding after prior treatment with a BTK inhibitor. The goal is to see if this new combination can effectively shrink tumors.
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
This Phase 2 trial studies whether adding polatuzumab vedotin and rituximab to bendamustine (a chemotherapy combination) can help people with mantle cell lymphoma that has come back or is not responding after a BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib). If you qualify, you’ll be checked carefully to make sure your body can safely handle the treatment.
This trial tests a combination of three drugs—sonrotoclax, zanubrutinib, and a CD20 antibody—as a first treatment for mantle cell lymphoma. It aims to see if this new combination is safe and effective for patients who have not yet received any treatment.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.